Clontech Laboratories, Inc. & TET Systems Announce the Broadening of Their License Agreement and the Upcoming Launch of the New Tet-On® 3G(TM) Inducible Expression System
The Tet-On 3G Inducible Expression System provides highly inducible, sensitive control of gene expression. It includes two novel components, the rights to which were acquired by TET in 2009: (i) an improved transcriptional activator developed by scientists at the Academic Medical Center at the University of Amsterdam (AMC) in the Netherlands, and (ii) a novel minimal Tet promoter developed at the University of Heidelberg in Germany.
The Tet-System currently marketed by Clontech is already the gold standard for regulated gene expression, as measured by more than 7,000 peerreviewed scientific publications. The new Tet-On 3G Inducible Expression System offers researchers even greater control of gene regulation due to lower expression in the noninduced state, even in transient transfection settings. The system's tenfold increased sensitivity for the inducing agent (Doxycycline) will also expand the longestablished benefits of dynamic transactivation, particularly for in vivo models.
Carol Lou, General Manager of Clontech Laboratories, Inc., comments: "Clontech has a long history of leadership in developing technologies for gene delivery and expression, and a longstanding partnership with TET Systems. We are pleased to continue and extend this history by adding the Tet-On 3G Inducible Expression System to our portfolio of Tet System Products, which also includes our inducible Lenti-X(TM) systems."
Clontech is launching a broad suite of Tet-On 3G Inducible Expression Systems, including different promoters, fluorescent markers, and bicistronic systems, which will be available August 2nd, 2010.
About Clontech Laboratories, Inc. - www.clontech.com
Clontech Laboratories, Inc., a whollyowned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Clontech and Takara brands. Key products include highperformance qPCR and PCR reagents (including the Ex Taq(TM) , LA Taq(TM) , Titanium(TM) , and Advantage® enzymes); RT enzymes and SMART(TM) library construction kits; the innovative In-Fusion(TM) cloning system; Tetbased inducible gene expression systems; and a range of Macherey-Nagel nucleic acid purification tools. These and other products support applications including gene discovery, regulation, and function; protein expression and purification; RNAi and stem cell studies; and plant and food research. For more information, visit www.clontech.com.
About Takara Bio Inc. - www.takara-bio.com
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is a worldstandard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cellbased therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com.
About TET Systems Holding GmbH & Co. KG
TET Systems is a privately held company located in Heidelberg, Germany. TET Systems was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms. TET Systems owns a broad patent portfolio covering the technology organized in six patent families comprising 35 granted patents and 15 patent applications. TET Systems markets licenses to the Tet Technology. To date, more than 150 organizations have licensed the Tet Technology including academic institutions and research foundations. The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2006) being Tet Technology licensees.